synapcell releases screening offer for the mtle mouse model
sCREENING STUDY : A new milestone for our MTLE model of focal EPILEPSY!
In Brief
🌐 Building on our 20 years preclinical expertise in epilepsy, our commitment to the CNS biotech community is stronger than ever.
Over the last two decades, our MTLE mouse model has been a trusted decision-making tool for our Sponsors. Recognized as a pharmaco-resistant model of epilepsy and used as part of the ETSP program, it contributed to the screening of a library of promising Anti-Seizure-Medications (ASMs).
get reliable entry-level data
🚀 Today, we’re excited to unveil our new Screening protocol, a perfect fit for proof-of-concept studies to IND-enabling studies:
Key Features
- N= 8 animals
- Several leads tested at the same time
- Cost-efficient study
- Decisive dataset
Benefits
- Fast-turnaround and time-efficient
- Decision-driving data
- Compelling proof-of-concept
A first step to the clinical trials
- A recognized pharmaco-resistant model of epilepsy
- Screening of a library of Anti-Seizure-Medications for CNS actors
example of screening study
- 12 COMPOUNDS | 1 dose
- N=8 MTLE mice per condition
- Quantification by EEG
